Latest Breaking News On - Chief executive officer elect - Page 2 : comparemela.com

AutoZone Announces Completion of Leadership Transition Plan

AutoZone Announces Completion of Leadership Transition Plan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Brian campbellDavid mckinneyPhil danieleAutozone incLeadership transition planChief executive officer electChief executive officerBill rhodesExecutive chairman

Breaking news | Latest News and News Headlines

No Cookies

New south walesWestern australiaSouth adelaideSouth australiaIsrael generalIsaac heeneyDaniel andrewsJack ginnivanYuri kouzminKeryn stevensRicky pontingPhil hillyardJason mccawleyDamien oliverAndrew dillonLisa christie

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Thera

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Ce.

Samit hirawatBristol myers squibbGiovanni caforioCharles baumChris boernerEvercore incDrug administrationMirati therapeutics incKirkland ellisHead of global drug developmentMorgan stanley coCenterview partnersClinical development in combinationSecurities exchangeMeagher flomAcquire mirati

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Samit hirawatCharles baumBristol myers squibbChris boernerGiovanni caforioCenterview partnersMorgan stanley coClinical development in combinationHead of global drug developmentMeagher flomSecurities exchangeDrug administrationKirkland ellisMirati therapeutics incEvercore incAcquire mirati

Bristol Myers Squibb (BMY) to acquire Mirati Therapeutics (MRTX) for $58/share plus CVR

Bristol Myers Squibb (BMY) to acquire Mirati Therapeutics (MRTX) for $58/share plus CVR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibbSamit hirawatGiovanni caforioCharles baumChris boernerDrug administrationMirati therapeutics incHead of global drug developmentMirati therapeuticsContingent value rightMirati boardsNon small cell lung cancerChief executive officerBoard chairBristol myersExecutive vice president